CASP3 and rheumatoid arthritis: GalXM treatment seemed to induce an increase of caspase-3 single positive T cells, an increase particularly evident in RA T cells (GalXM-untreated vs GalXM-treated cells: 53.5% vs 58.7% in control, 46.6% vs 55.1% in RA).